Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at delrayresearch.com, will continue to monitor these healthtech companies to see if the momentum continues. DelrayResearch.com is also looking into these tickers DAWN, COGT, RMD, BSX, RACE, RTX..
Recent ARWR Stock Price: $36.12
Summary: Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
Patrick Trucchio analyst at H.C. Wainwright reiterates coverage on Arrowhead Pharmaceuticals (ARWR) stock in the energy sector with a Buy rating and has set ARWR's stock price target at $ 90.
In addition, TradingView issued a Buy rating for ARWR over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ARWR. delrayresearch.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ARWR, please click here >>
Castle Biosciences, CSTL
Recent CSTL Stock Price: $14.72
Summary: Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.
Kyle Mikson analyst at Canaccord Genuity reiterates coverage on Castle Biosciences (CSTL) stock in the energy sector with a Buy rating and has set CSTL's stock price target at $ 40.
In addition, TradingView issued a Sell rating for CSTL over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on CSTL. delrayresearch.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on CSTL, please click here >>
Merck & Company, MRK
Recent MRK Stock Price: $110.01
Summary: Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
David Toung analyst at Argus Research reiterates coverage on Merck & Company (MRK) stock in the energy sector with a Buy rating and has set MRK's stock price target at $ 125.
In addition, TradingView issued a Sell rating for MRK over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MRK. delrayresearch.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MRK, please click here >>
The editors at delrayresearch.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
Click here to join thousands of investors who have already signed up for a free subscription to consumer staples stocks newsletter PoliticsAndMyPortfolio.com.
==============================================================================
